(Q34129926)

31 July 2017

1 reference

title

Differentiation of multiple sclerosis subtypes: implications for treatment (English)

1 reference

31 July 2017

0 references

Andreas Bitsch

1

1 reference

31 July 2017

Wolfgang Brück

series ordinal

2

1 reference

31 July 2017

publication date

1 January 2002

1 reference

31 July 2017

1 reference

31 July 2017

volume

16

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

405-418

1 reference

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

31 July 2017

cites work

1 reference

12 December 2020

Primary progressive multiple sclerosis

1 reference

12 December 2020

Pregnancy and multiple sclerosis: a 2-year experience

1 reference

12 December 2020

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up

1 reference

12 December 2020

A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials

1 reference

12 December 2020

A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases

1 reference

12 December 2020

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

12 December 2020

Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

1 reference

12 December 2020

Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy

1 reference

12 December 2020

Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination

1 reference

12 December 2020

Mechanisms of action of intravenous immunoglobulin (IVIG).

1 reference

12 December 2020

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

12 December 2020

Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

1 reference

12 December 2020

Progressive forms of MS: classification streamlined or consensus overturned?

1 reference

12 December 2020

Intravenous immunoglobulins in multiple sclerosis

1 reference

12 December 2020

Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia

1 reference

12 December 2020

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

Transitional progressive multiple sclerosis: a clinical and imaging study.

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

12 December 2020

A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis

1 reference

12 December 2020

A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis

1 reference

12 December 2020

Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis

1 reference

12 December 2020

Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]

1 reference

12 December 2020

Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring

1 reference

12 December 2020

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

1 reference

12 December 2020

No evidence of CNS infection with Chlamydia pneumoniae in patients with multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. BMT-MS Study Group.

1 reference

12 December 2020

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Bone marrow transplantation in multiple sclerosis

1 reference

12 December 2020

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

12 December 2020

The optic neuritis treatment trial: three-year follow-up results

1 reference

12 December 2020

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

1 reference

12 December 2020

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

1 reference

12 December 2020

Hematopoietic stem cell transplantation of multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Overview of azathioprine treatment in multiple sclerosis

1 reference

12 December 2020

Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study

1 reference

12 December 2020

Biological markers in body fluids for activity and progression in multiple sclerosis

1 reference

12 December 2020

Optic neuritis in chronic relapsing experimental allergic encephalomyelitis in Biozzi ABH mice: Demyelination and fast axonal transport changes in disease

1 reference

12 December 2020

T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients

1 reference

12 December 2020

Primary and transitional progressive MS: a clinical and MRI cross-sectional study

1 reference

12 December 2020

The natural history of multiple sclerosis: update 1998

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation

1 reference

12 December 2020

Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis

1 reference

12 December 2020

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy

1 reference

12 December 2020

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

12 December 2020

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

12 December 2020

Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study

1 reference

12 December 2020

Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses

1 reference

12 December 2020

Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules

1 reference

12 December 2020

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy

1 reference

12 December 2020

Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms

1 reference

12 December 2020

An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis

1 reference

12 December 2020

A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations

1 reference

12 December 2020

Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis

1 reference

12 December 2020

10.2165/00023210-200216060-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1006946385

0 references

1 reference